Venetoclax Combination Therapy and Elderly AML Patients

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Treatment cessation using venetoclax-based therapy for older patients with AMLПодробнее

Novel approaches to treating AML in elderly patientsПодробнее

Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 2Подробнее

Venetoclax-IDH inhibitor combination therapy for AMLПодробнее

Idasanutlin and venetoclax in elderly R/R AMLПодробнее

Naval Daver, ASH 2019: Venetoclax in Combination with Idasanutlin in Relapsed or Refractory AMLПодробнее

Dr. DiNardo on the Efficacy of Venetoclax Combination Therapies in AMLПодробнее

Venetoclax based combination therapy in AML: a real-world retrospective analysisПодробнее

Daniel Pollyea | ASH 2018 | Venetoclax plus HMAs in patients with AML unfit for intensive therapyПодробнее

CAVEAT: venetoclax and high dose chemo for elderly AMLПодробнее

A new era for elderly AML patientsПодробнее

Courtney DiNardo | ASCO 2018 | Venetoclax plus HMAs in elderly AML patientsПодробнее

Venetoclax and FLT3 inhibitor combination therapy for AMLПодробнее

Update on venetoclax combination trials for elderly AML from ASH 2017Подробнее

Is venetoclax a game changer in AML therapy?Подробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Current research in elderly, untreated AML: venetoclax combinationsПодробнее

Venetoclax combinations effective in elderly AMLПодробнее